Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

@article{Koolen2012AssociationOP,
  title={Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy},
  author={Bas B. Koolen and Marie Jeanne T. F. D. Vrancken Peeters and Jelle Wesseling and Esther H. Lips and Wouter V. Vogel and Tjeerd S. Aukema and Erik van Werkhoven and Kenneth G. A. Gilhuijs and Sjoerd Rodenhuis and Emiel J. Th. Rutgers and Renato A. Vald{\'e}s Olmos},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2012},
  volume={39},
  pages={1830-1838}
}
The aim of this study was to evaluate the association of primary tumour 18F-fluorodeoxyglucose (FDG) uptake with clinical, histopathological and molecular characteristics of breast cancer patients scheduled for neoadjuvant chemotherapy. Second, we wished to establish for which patients pretreatment positron emission tomography (PET)/CT could safely be omitted because of low FDG uptake. PET/CT was performed in 214 primary stage II or III breast cancer patients in the prone position with hanging… CONTINUE READING